<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">actabiomedica</journal-id><journal-title-group><journal-title xml:lang="ru">Acta Biomedica Scientifica</journal-title><trans-title-group xml:lang="en"><trans-title>Acta Biomedica Scientifica</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2541-9420</issn><issn pub-type="epub">2587-9596</issn><publisher><publisher-name>Scientific Centre for Family Health and Human Reproduction Problems</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.29413/ABS.2026-11.3.5</article-id><article-id custom-type="elpub" pub-id-type="custom">actabiomedica-6173</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКАЯ ЛАБОРАТОРНАЯ ДИАГНОСТИКА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL LABORATORY DIAGNOSIS</subject></subj-group></article-categories><title-group><article-title>Сравнительная характеристика магнитоконтрастных свойств гадолинийсодержащих препаратов для МРТ-диагностики</article-title><trans-title-group xml:lang="en"><trans-title>Comparative evaluation of the magnetic resonance contrast properties of gadolinium-based contrast agents</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1052-4601</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Соседова</surname><given-names>Л. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Sosedova</surname><given-names>L. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Соседова Лариса Михайловна – доктор медицинских наук, профессор, заведующая лабораторией биомоделирования и трансляционной медицины.</p><p>665827, Иркутская область, Ангарск, микрорайон 12а, д. 3</p></bio><bio xml:lang="en"><p>Larisa M. Sosedova –Dr. Sc (Med), professor, head of the laboratory of biomodelling and translational medicine.</p><p>12a Microdistrict, 3, Irkutsk Region, Angarsk 665827</p></bio><email xlink:type="simple">sosedlar@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8165-8052</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Вокина</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Vokina</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Вокина Вера Александровна – кандидат биологических наук, старший научный сотрудник лаборатории биомоделирования и трансляционной медицины.</p><p>665827, Иркутская область, Ангарск, микрорайон 12а, д. 3</p></bio><bio xml:lang="en"><p>Vera A. Vokina – Cand. Sc. (Biol.), senior researcher at the laboratory of biomodelling and translational medicine.</p><p>12a Microdistrict, 3, Irkutsk Region, Angarsk 665827</p></bio><email xlink:type="simple">vokina.vera@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6100-6292</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Новиков</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Novikov</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Новиков Михаил Александрович – кандидат биологических наук, старший научный сотрудник лаборатории биомоделирования и трансляционной медицины.</p><p>665827, Иркутская область, Ангарск, микрорайон 12а, д. 3</p></bio><bio xml:lang="en"><p>Mikhail A. Novikov – Cand. Sc. (Biol.), senior research officer at the Laboratory of Biomodeling and Translational Medicine.</p><p>12a Microdistrict, 3, Irkutsk Region, Angarsk 665827</p></bio><email xlink:type="simple">novik-imt@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0665-8060</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Титов</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Titov</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Титов Евгений Алексеевич – кандидат биологических наук, старший научный сотрудник лаборатории биомоделирования и трансляционной медицины.</p><p>665827, Иркутская область, Ангарск, микрорайон 12а, д. 3</p></bio><bio xml:lang="en"><p>Evgeny A. Titov – Cand. Sc. (Biol.), senior research officer at the Laboratory of Biomodeling and Translational Medicine.</p><p>12a Microdistrict, 3, Irkutsk Region, Angarsk 665827</p></bio><email xlink:type="simple">g57097@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6012-0173</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Панкова</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Pankova</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Панкова Анна Александровна – младший научный сотрудник лаборатории биомоделирования и трансляционной медицины.</p><p>665827, Иркутская область, Ангарск, микрорайон 12а, д. 3</p></bio><bio xml:lang="en"><p>Pankova Anna Aleksandrovna – junior research assistant at the laboratory of biomodelling and translational medicine.</p><p>12a Microdistrict, 3, Irkutsk Region, Angarsk 665827</p></bio><email xlink:type="simple">nyuta.pankova.96@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-0706-8692</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Конькова</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Konkova</surname><given-names>T. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Конькова Татьяна Владимировна – кандидат химических наук, научный сотрудник лаборатории наночастиц.</p><p>630090, Новосибирск, ул. Институтская, 3</p></bio><bio xml:lang="en"><p>Tatyana V. Kon’kova – Cand. Sc. (Chem.), researcher at the Nanoparticles Laboratory of Voevodsky Institute of Chemical Kinetics and Combustion SB of the RAS.</p><p>630090, Novosibirsk, Institutskaya Street, 3</p></bio><email xlink:type="simple">konbuivol_2@yahoo.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9751-6454</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сухов</surname><given-names>Б. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Sukhov</surname><given-names>B. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сухов Борис Геннадьевич – кандидат химических наук, ведущий научный сотрудник лаборатории наночастиц.</p><p>630090, Новосибирск, ул. Институтская, 3</p></bio><bio xml:lang="en"><p>Boris G. Sukhov – Cand. Sc. (Chem.), leading researcher at the Nanoparticles Laboratory of Voevodsky Institute of Chemical Kinetics and Combustion, SB of the RAS.</p><p>630090, Novosibirsk, Institutskaya Street, 3</p></bio><email xlink:type="simple">boris_sukhov@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Восточно-Сибирский институт медико-экологических исследований»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>East-Siberian Institute of Medical and Ecological Research</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУН «Институт химической кинетики и горения им. В.В. Воеводского» СО РАН</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Voevodsky Institute of Chemical Kinetics and Combustion, SB of the RAS</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>02</day><month>08</month><year>2026</year></pub-date><volume>11</volume><issue>3</issue><fpage>37</fpage><lpage>46</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Соседова Л.М., Вокина В.А., Новиков М.А., Титов Е.А., Панкова А.А., Конькова Т.В., Сухов Б.Г., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Соседова Л.М., Вокина В.А., Новиков М.А., Титов Е.А., Панкова А.А., Конькова Т.В., Сухов Б.Г.</copyright-holder><copyright-holder xml:lang="en">Sosedova L.M., Vokina V.A., Novikov M.A., Titov E.A., Pankova A.A., Konkova T.V., Sukhov B.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.actabiomedica.ru/jour/article/view/6173">https://www.actabiomedica.ru/jour/article/view/6173</self-uri><abstract><sec><title>Обоснование</title><p>Обоснование. Ограничения применения гадолинийсодержащих рентгеноконтрастных веществ, обусловленные развитием острых и отдаленных осложнений, стимулируют поиск новых, более безопасных и эффективных форм на основе наночастиц гадолиния.</p></sec><sec><title>Цель работы</title><p>Цель работы. Сравнительная оценка магнитоконтрастных свойств нанокомпозита гадолиния и содержащего гадолиний диагностического препарата.</p></sec><sec><title>Методы</title><p>Методы. Динамика органного накопления и визуальной МРТ-картины изучены на 5-ти здоровых белых крысах-самках линии Wistar на аппарате Siemens Avanto с магнитным полем 1,5 Тл. Для проведения МРТ анестезированных животных укладывали в вентральном положении в катушку, предназначенную для головы, проводили предварительное исследование на МРТ-томографе, затем в латеральную хвостовую вену или в брюшную полость с помощью катетера вводили раствор нанокомпозита гадолиния или препарата сравнения (Омнискан®) в эквивалентных по гадолинию дозах и проводили повторное МРТ-исследование, делая снимки через каждые 2–3 минуты. Центром области исследования были брюшная полость и забрюшинное пространство с захватом в поле зрения грудной клетки.</p></sec><sec><title>Результаты</title><p>Результаты. Выполненный сравнительный анализ показал, что наночастицы гадолиния, стабилизированные арабиногалактаном, обладают магнитоконтрастными свойствами, доказательством чему явилось усиление T1-взвешенного изображения в паренхиме печени при внутривенном введении и брюшной полости при внутрибрюшинном введении. Магнитоконтрастное изображение почек, мочевого пузыря при введении препарата Омнискан® выше, чем при введении нанокомпозита гадолиния. Однако максимальная величина коэффициента контрастирования нанокомпозита гадолиния в паренхиме печени возрастала по сравнению с исходным состоянием на 20 %, при введении Омнискана® наблюдалось усиление интенсивности Т1-взвешенного изображения паренхимы печени на 13 %.</p></sec><sec><title>Заключение</title><p>Заключение. Использование нанокомпозита гадолиния является перспективным для МРТ-диагностики. На данном этапе пока преждевременно говорить о возможностях применения исследуемого нанокомпозита гадолиния в клинической практике, требуется более детальное рассмотрение его влияния на процессы релаксации как в нормальных, так и в патологически измененных тканях.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. Restrictions on the use of gadolinium-containing radiocontrast agents due to the risk of acute and long-term complications drive the search for new, safer, and more effective gadolinium-based nanoparticle formulations.</p></sec><sec><title>Aim</title><p>Aim. Comparative assessment of the magnetocontrast properties of a gadolinium nanocomposite and a gadolinium-based contrast agent.</p></sec><sec><title>Methods</title><p>Methods. The dynamics of organ accumulation and visual MRI patterns were studied in 5 healthy female Wistar rats using a Siemens Avanto device with a magnetic field of 1.5 T. Anesthetized animals were placed in a ventral position within the head coil, after which a preliminary MRI scan was performed. A gadolinium nanocomposite solution and a reference agent (Omniscan®) were injected at equivalent gadolinium doses into the lateral tail vein or into the abdominal cavity, followed by repeat MRI scans with image acquisition every 2–3 minutes. The primary imaging areas were the abdominal cavity and retroperitoneal space, including the thoracic cavity.</p></sec><sec><title>Results</title><p>Results. Comparative analysis showed that gadolinium nanoparticles stabilized with arabinogalactan exhibit magnetocontrast properties, as evidenced by T1-weighted image enhancement of the liver parenchyma after intravenous administration and of the abdominal cavity after intraperitoneal administration. The magnetocontrast image of the kidneys and bladder was higher after Omniscan® administration than after gadolinium nanocomposite administration. However, the maximum contrast coefficient of the gadolinium nanocomposite in the liver parenchyma increased by 20 % compared to baseline. Omniscan® administration resulted in a 13 % increase in T1-weighted image intensity of the liver parenchyma.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>гадолиний</kwd><kwd>нанокомпозит</kwd><kwd>наночастицы</kwd><kwd>магнитоконтрастные свойства</kwd><kwd>белые крысы</kwd></kwd-group><kwd-group xml:lang="en"><kwd>gadolinium</kwd><kwd>nanocomposite</kwd><kwd>nanoparticles</kwd><kwd>magnetocontrast properties</kwd><kwd>white rats</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование поддержано грантом Российского научного фонда. Проект №25-25-00036 «Токсичность и диагностические свойства перспективного контрастирующего агента, содержащего наночастицы гадолиния, инкапсулированные в полимерную матрицу арабиногалактана». Выражаем глубокую признательность Мануйловой Виктории Викторовне – директору сети ветеринарных клиник «Бэст» (г. Новосибирск) за предоставленную возможность проведения МРТ белым крысам</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Rudnick MR, Wahba IM, Leonberg-Yoo AK, Miskulin D, Litt HI. Risks and Options with Gadolinium-Based Contrast Agents in Patients with CKD: A Review. Am J Kidney Dis. 2021; 77(4): 517–528. doi: 10.1053/j.ajkd.2020.07.012</mixed-citation><mixed-citation xml:lang="en">Rudnick MR, Wahba IM, Leonberg-Yoo AK, Miskulin D, Litt HI. Risks and Options with Gadolinium-Based Contrast Agents in Patients with CKD: A Review. Am J Kidney Dis. 2021; 77(4): 517–528. doi: 10.1053/j.ajkd.2020.07.012</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Parillo M, Mallio CA, Van der Molen AJ, Rovira À, Ramalho J, Ramalho M, et al. Skin Toxicity After Exposure to Gadolinium-Based Contrast Agents in Normal Renal Function, Using Clinical Approved Doses: Current Status of Preclinical and Clinical Studies. Invest Radiol. 2023; 58(8): 530–538. doi: 10.1097/RLI.0000000000000973</mixed-citation><mixed-citation xml:lang="en">Parillo M, Mallio CA, Van der Molen AJ, Rovira À, Ramalho J, Ramalho M, et al. Skin Toxicity After Exposure to Gadolinium-Based Contrast Agents in Normal Renal Function, Using Clinical Approved Doses: Current Status of Preclinical and Clinical Studies. Invest Radiol. 2023; 58(8): 530–538. doi: 10.1097/RLI.0000000000000973</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ramalho J, Ramalho M. Gadolinium Deposition and Chronic Toxicity. Magn Reson Imaging Clin N Am. 2017; 25(4): 765–778. doi: 10.1016/j.mric.2017.06.007</mixed-citation><mixed-citation xml:lang="en">Ramalho J, Ramalho M. Gadolinium Deposition and Chronic Toxicity. Magn Reson Imaging Clin N Am. 2017; 25(4): 765–778. doi: 10.1016/j.mric.2017.06.007</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Layne Kerry A, Dargan Paul I, Archer John RH, Wood David M. Gadolinium deposition and the potential for toxicological sequelae – A literature review of issues surrounding gadolinium-based contrast agents. Br. J. Clin. Pharmacol. 2018; 84(11): 2522–2534. doi: 10.1111/bcp.13718</mixed-citation><mixed-citation xml:lang="en">Layne Kerry A, Dargan Paul I, Archer John RH, Wood David M. Gadolinium deposition and the potential for toxicological sequelae – A literature review of issues surrounding gadolinium-based contrast agents. Br. J. Clin. Pharmacol. 2018; 84(11): 2522–2534. doi: 10.1111/bcp.13718</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Chauhan G, Upadhyay A. Gadolinium-based contrast agent-induced neurotoxicity: seeing is believing! BMJ Case Rep. 2021; 14(1): e241372. doi: 10.1136/bcr-2020241372</mixed-citation><mixed-citation xml:lang="en">Chauhan G, Upadhyay A. Gadolinium-based contrast agent-induced neurotoxicity: seeing is believing! BMJ Case Rep. 2021; 14(1): e241372. doi: 10.1136/bcr-2020241372</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Sieber Martin A, Lengsfeld Ph, Frenzel T, Golfier S, Schmitt-Willich H, Siegmund F, et al. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol. 2008; 18(10): 2164-73. doi: 10.1007/s00330-008-0977-y</mixed-citation><mixed-citation xml:lang="en">Sieber Martin A, Lengsfeld Ph, Frenzel T, Golfier S, Schmitt-Willich H, Siegmund F, et al. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol. 2008; 18(10): 2164-73. doi: 10.1007/s00330-008-0977-y</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Rogosnitzky M, Branch S. Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms. Biometals. 2016; 29: 365–376. doi: 10.1007/s10534-016-9931-7</mixed-citation><mixed-citation xml:lang="en">Rogosnitzky M, Branch S. Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms. Biometals. 2016; 29: 365–376. doi: 10.1007/s10534-016-9931-7</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Mercantepe T, Tumkaya L, Celiker FB, Topal SZ, Cinar S, Akyildiz K, et al. Effects of gadolinium-based MRI contrast agents on liver tissue. J. Magn. Reson. Imaging. 2018; 48: 1367–1374. doi: 10.1002/jmri.26031</mixed-citation><mixed-citation xml:lang="en">Mercantepe T, Tumkaya L, Celiker FB, Topal SZ, Cinar S, Akyildiz K, et al. Effects of gadolinium-based MRI contrast agents on liver tissue. J. Magn. Reson. Imaging. 2018; 48: 1367–1374. doi: 10.1002/jmri.26031</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Coimbra S, Rocha S, Sousa NReis, Catarino C, Belo L, Bronze-da-Rocha E, et al. Toxicity Mechanisms of Gadolinium and Gadolinium-Based Contrast Agents-A Review. Int. J. Mol. Sci. 2024; 25(7): 4071. doi: 10.3390/ijms25074071</mixed-citation><mixed-citation xml:lang="en">Coimbra S, Rocha S, Sousa NReis, Catarino C, Belo L, Bronze-da-Rocha E, et al. Toxicity Mechanisms of Gadolinium and Gadolinium-Based Contrast Agents-A Review. Int. J. Mol. Sci. 2024; 25(7): 4071. doi: 10.3390/ijms25074071</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kotb S, Detappe A, Lux F, Appaix F, Barbier EL, Tran VL, et al. Gadolinium-Based Nanoparticles and Radiation Therapy for Multiple Brain Melanoma Metastases: Proof of Concept before Phase I Trial. Theranostics. 2016; 6(3): 418-27. doi: 10.7150/thno.14018</mixed-citation><mixed-citation xml:lang="en">Kotb S, Detappe A, Lux F, Appaix F, Barbier EL, Tran VL, et al. Gadolinium-Based Nanoparticles and Radiation Therapy for Multiple Brain Melanoma Metastases: Proof of Concept before Phase I Trial. Theranostics. 2016; 6(3): 418-27. doi: 10.7150/thno.14018</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Maury P, Texier M, Genestie C, Morice P, Bockel S, Gouy S, et al. Theragnostic Gadolinium-Based Nanoparticles Safely Augment X-ray Radiation Effects in Patients with Cervical Cancer. ACS Nano. 2024; 18(26): 16516-16529. doi: 10.1021/acsnano.3c12537</mixed-citation><mixed-citation xml:lang="en">Maury P, Texier M, Genestie C, Morice P, Bockel S, Gouy S, et al. Theragnostic Gadolinium-Based Nanoparticles Safely Augment X-ray Radiation Effects in Patients with Cervical Cancer. ACS Nano. 2024; 18(26): 16516-16529. doi: 10.1021/acsnano.3c12537</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Сухов Б.Г., Конькова Т.В., Иванов А.В. Водорастворимые магнитоактивные нанобиокомпозиты флавоноидных комплексов гадолиния на основе природного конъюгата арабиногалактана с биофлавоноидами и способ получения этих нанобиокомпозитов. Патент РФ № 2706705. 2019. Опуб. 20.11.2019.</mixed-citation><mixed-citation xml:lang="en">Sukhov BG, Konkova TV, Ivanov AV. Water-soluble magnetoactive nanobiocomposites of gadolinium flavonoid complexes based on a natural conjugate of arabinogalactan with bioflavonoids and a method for obtaining these nanobiocomposites. Patent RF № 2706705. – 2019. Publ. 20.11.2019 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Trofimov BA, Sukhov BG, Aleksandrova GP, Medvedeva SA, Grishchenko LA, Mal’kina AG, et al. Arabinogalactan-based nanocomposites with magnetic, optical, catalytic and biologically active properties. Doklady Akademii Nauk. 2003; 393(5): 634-635.</mixed-citation><mixed-citation xml:lang="en">Trofimov BA, Sukhov BG, Aleksandrova GP, Medvedeva SA, Grishchenko LA, Mal’kina AG, et al. Arabinogalactan-based nanocomposites with magnetic, optical, catalytic and biologically active properties. Doklady Akademii Nauk. 2003; 393(5): 634-635.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Куценко С.А. Основы токсикологии. М.: Фолиант; 2004. [Kutsenko SA. Fundamentals of Toxicology. M.: Foliant; 2004. (In Russ.).</mixed-citation><mixed-citation xml:lang="en">Куценко С.А. Основы токсикологии. М.: Фолиант; 2004. [Kutsenko SA. Fundamentals of Toxicology. M.: Foliant; 2004. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Гомзикова М.О., Маланьева А.Г., Сираева З.Ю. Основы проведения биомедицинских исследований на лабораторных животных: учеб. Пособие. Казань: ИД «МеДДоК»; 2021.</mixed-citation><mixed-citation xml:lang="en">Gomzikova MO, Malanyeva AG, Siraeva ZYu. Fundamentals of biomedical research on laboratory animals: textbook. Kazan: PH “Meddock”; 2021. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Kaneo Y, Ueno T, Tanaka T, Jwase H, Yamaguchi Y, Uemura T. Pharmacokinetics and biodisposition of fluorescein-labeled arabinogalactan in rats. Jnt. J. Pharm. 2000; 201(1): 59–69. doi: 10.1016/s0378-5173(00)00405-1</mixed-citation><mixed-citation xml:lang="en">Kaneo Y, Ueno T, Tanaka T, Jwase H, Yamaguchi Y, Uemura T. Pharmacokinetics and biodisposition of fluorescein-labeled arabinogalactan in rats. Jnt. J. Pharm. 2000; 201(1): 59–69. doi: 10.1016/s0378-5173(00)00405-1</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Davies J, Siebenhandl-Wolff P, Tranquart F, Jones P, Evans P. Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration. Arch Toxicol. 2022; 96(2): 403–429. doi: 10.1007/s00204-021-03189-8</mixed-citation><mixed-citation xml:lang="en">Davies J, Siebenhandl-Wolff P, Tranquart F, Jones P, Evans P. Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration. Arch Toxicol. 2022; 96(2): 403–429. doi: 10.1007/s00204-021-03189-8</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
